SL
Silence Therapeutics plc
SLNCF · OTC
$4.40 +10.00% (+$0.40)
1M -11.11%
Market Cap $623.5M
P/E Ratio -
Div. Yield -
ROE 106.94%
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 16.21x
P/S 1,013.82x
PEG N/A
Growth
22 /100
Declining Book val. growth 41.33%
Rev. growth 68.27%
FCF growth N/A
Profitability
0 /100
Weak FCF margin 6,334.92%
Op. margin 9,439.19%
Gross margin 13.82%
Quality
0 /100
Poor Asset turnover 0.01x
ROA 56.34%
ROIC 61.89%
Debt
100 /100
Low Current ratio 7.42x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
17 /100
Unstable Profitable years 0
EPS volatility 64.32%
Beta 1.41x
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre SLNCF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain Gladstone Ross
Employees
88
Headquarters
London